Multiple sclerosis, relapsing-remitting has been the subject of sustained clinical investigation across multiple research sites.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID	Title	Status	Phase
NCT03500328	Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial	ACTIVE_NOT_RECRUITING	NA
NCT03689972	A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration	COMPLETED	PHASE3
NCT00930553	An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab	COMPLETED	PHASE3
NCT00306592	Natalizumab Re-Initiation of Dosing	COMPLETED	PHASE3
NCT00030966	Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis	COMPLETED	PHASE3
NCT00050778	A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis	COMPLETED	PHASE2
NCT05028634	Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy	COMPLETED	PHASE3
NCT00530348	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One	COMPLETED	PHASE3
NCT00548405	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two	COMPLETED	PHASE3
NCT02637856	A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)	COMPLETED	PHASE3

Related Pages

All Multiple sclerosis, relapsing-remitting trials All trials in Round Rock, United States